Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.47 |
| ▸ | ITGAV | P06756 | 4/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CALCRL | Q16602 | 9/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538078 | 1.00 | ITGB3 (0.47) | ITGB3ITGAVITGA2BHSD17B1OPRM1 | |
| SCHEMBL13688296 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGA2BOPRM1CALCRL | |
| SCHEMBL981045 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGA2BOPRM1CALCRL | |
| SCHEMBL4671293 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGA2BOPRM1CALCRL | |
| SCHEMBL12948918 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGA2BOPRM1CALCRL | |
| SCHEMBL6418802 | 0.85 | ITGB3 (0.56) | ITGB3ITGAVITGA2BOPRM1CALCRL | |
| SCHEMBL981179 | 0.85 | ITGB3 (0.56) | ITGB3ITGAVITGA2BOPRM1CALCRL | |
| SCHEMBL981119 | 0.85 | ITGB3 (0.56) | ITGB3ITGAVITGA2BOPRM1CALCRL | |
| SCHEMBL12922956 | 0.85 | ITGB3 (0.56) | ITGB3ITGAVITGA2BOPRM1CALCRL | |
| SCHEMBL14182026 | 0.85 | ITGB3 (0.44) | ITGB3ITGAVITGA2BOPRM1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415474-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | UBE INDUSTRIES (JP) | 2013-08-28 | — | — | EP | disclosed |
| EP-2221308-B1 | BENZAZEPINONE COMPOUND | UBE INDUSTRIES (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8377922-B2 | Benzazepinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20120095215-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF EYE DISEASES | UBE INDUSTRIES, LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415474-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100249396-A1 | BENZAZEPINONE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2221308-A1 | BENZAZEPINONE COMPOUND | Ube Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095215-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF EYE DISEASES | VEGFA, UACA, PGF | ITGB3 1280/4885ITGAV 2836/4885ITGA2B 2740/4885 |
| US-20100249396-A1 | BENZAZEPINONE COMPOUND | KCNJ11, KCNJ1, KCNJ2 | ITGB3 3002/4885ITGAV 3792/4885ITGA2B 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.